MTR
Chr 1AR5-methyltetrahydrofolate-homocysteine methyltransferase
Also known as: HMAG, MS, cblG
The 5-methyltetrahydrofolate-homocysteine methyltransferase catalyzes the final step in methionine biosynthesis as a cobalamin-dependent methionine synthase. Biallelic mutations cause homocystinuria-megaloblastic anemia (cblG complementation type) and increase susceptibility to neural tube defects through autosomal recessive inheritance. The pathogenic mechanism involves loss of enzyme function leading to impaired methionine synthesis and elevated homocysteine levels.
Definitive — sufficient evidence for diagnostic panels
Population Genetics & Constraint
gnomAD v4 — loss-of-function & missense intolerance
Typical tolerance to LoF variation
Moderately missense-constrained (top ~2.5%)
Predictions shown for reference only — model trained on dominant genes, not applicable to AR conditions.
The Badonyi & Marsh prediction model was trained exclusively on dominant disease genes. Predictions are not reliable for genes with autosomal recessive inheritance and are shown at reduced opacity for reference only.
Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.
ClinVar Variant Classifications
0 submitted variants in ClinVar
Protein Context — Lollipop Plot
MTR · protein map & ClinVar variants
Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.
3D Protein StructureAlphaFold
External Resources
Links to major genomics databases and tools
Clinical Trials
Active and recruiting trials from ClinicalTrials.gov
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
RECRUITINGStudy of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
ACTIVE NOT RECRUITINGClinical and Laboratory Study of Methylmalonic Acidemia
RECRUITINGA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
RECRUITINGA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RECRUITINGExternal Resources
Links to major genomics databases and tools